3rd Antigen Specific Immune Tolerance Summit

When:
Tuesday, Feb 25, 2020 9:00a -
Thursday, Feb 27, 2020 6:00p

Where:
The Colonnade Hotel
120 Huntington Avenue
Boston, MA 02116

EventScheduled OfflineEventAttendanceMode

Admission:
$3799

Categories:
Lectures & Conferences

Event website:
https://go.evvnt.com/515268-2?pid=5248

Accelerate the progression of ethical and effective antigen specific immunotherapies through the clinic, optimize the discovery of novel targets and explore novel therapeutic approaches harnessing combination therapies.Building on the success of the 2019 meeting, the 3rd Antigen Specific Immune Tolerance Summit (ASIT) returns to Boston on February 25-27, 2020. The meeting will bring together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. With momentum building for antigen specific immunotherapies, ASIT 2020 is the only antigen specific summit offering thought leading content to drive the field towards a more precise and ethical antigen-specific approach to drug development.


URLs:
Tickets https://go.evvnt.com/515268-0?pid=5248
Brochure https://go.evvnt.com/515268-3?pid=5248


Prices:
Conference + 2 Workshops (Industry) : USD 3799.0,
Conference + 1 Workshop (Industry) : USD 3399.0,
Conference Only (Industry) : USD 2899.0,
Workshop Day Only (Industry) : USD 998.0,
Conference + 2 Workshops (Academic): USD 2699.0,
Conference + 1 Workshop (Academic): USD 2299.0,
Conference Only (Academic): USD 1899.0,
Workshop Day Only (Academic): USD 998.0


Speakers:
Kurt Griffin , Associate Professor, University of South Dakota Sanford School of Medicine, Andreas Lutterotti , Head of Experimental Therapies Research , University Hospital Zurich, Stephen Miller, Co-Founder of Cour Pharmaceuticals; Professor of Microbiology- Immunology, Northwestern University Medical School, Aaron Michels Associate Professor of Pediatrics Medicine, and Immunology, Barbara Davis Center for Diabetes, University of Colorado; Chief Scientific Officer IM Therapeutics, Shahrokh Shabahang , Chief Innovation Officer, AdiTxt Therapeutics, Kei Kishimoto , Chief Scientific Officer, Selecta Biosciences, David Alleva , Executive Director, Akston Biosciences, Giles Benichou , Associate Professor of Surgery, Harvard Medical School, Senior Immunologist Massachusetts General Hospital, Emilio Flano, Director and Head of Immunology Discovery , Merck and Co, Matthias von Herrath , Vice President, Novo Nordisk, Martin Roland, Head - Department of Neuroimmunology and Multiple Sclerosis Research, University Hospital Zurich, Dolly Tyan Professor, Emerita of Pathology Stanford, University School of Medicine, Lawrence Steinman, Professor of Neurology, Neurological Sciences and Pediatrics, Stanford University, Anne De Groot Founder, Chief Executive Officer and Chief Scientific Officer, Epivax, Ben Williams, Program Officer for the Type 1 Diabetes (T1D) Program, Helmsley Charitable Trust, Giorgio Raimondi, Associate Scientific Director for Transplant Immunology , John Hopkins School of Medicine, Cory Berkland, Distinguished Professor, School of Pharmacy Pharmaceutical Chemistry, University of Kansas, Todd Zion, President and Chief Executive Officer, Akston Biosciences, Garth Ringheim, Director Immunology Therapeutic Area, Clarivate Analysis, Curtis Ruegg, President and Chief Executive Officer, Parvus Therapeutics, Inc., Jack Ragheb, Senior Medical Fellow for Immunology in Global Patient Safety, Eli Lilly and Co., Arpita Maiti, Executive Director and Global Head, Global Head Pfizer, Kristina M. Harris Director, Biomarker and Discovery Research, Immune Tolerance Network, Joshua Sestak, President and Chief Executive Officer, Founder Orion BioScience, Monali Manohar, Life Science Research Scientist Stanford, University School of Medicine, Colin Dayan, Professor of Clinical Diabetes and Metabolism Cardiff, University School of Medicine, David Wraith, Director of the Institute of Immunology and Immunotherapy , University of Birmingham, Stephan Kontos, Founder and Chief Scientific Officer, Anokion, Simi Ahmed, Director of Research and Lead of the Immune Therapies Program, JDRF, Waldo Concepcion, Professor of Surgery (Abdominal Transplantation) and of Pediatrics (Nephrology), Stanford University Medical Center, Amy Rosenberg, Director - Therapeutic Proteins and CDER, FDA

Share this event

Add to:

Reddit
02/25/2020 09:00:00 02/27/2020 18:00:00 America/New_York 3rd Antigen Specific Immune Tolerance Summit Accelerate the progression of ethical and effective antigen specific immunotherapies through the clinic, optimize the discovery of novel targets and explore novel therapeutic approaches harnessing ...

https://www.thebostoncalendar.com/events/3rd-antigen-specific-immune-tolerance-summit The Colonnade Hotel, Boston, MA 02116 false MM/DD/YYYY

Sponsored events